Drugs /

adagloxad simolenin

Back to Drugs List

Overview

NCI Definition [1]:
A carbohydrate-based immunostimulant comprised of the Globo H hexasaccharide 1 (Globo H) epitope linked to the immunostimulant carrier protein keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration of adagloxad simolenin, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. Globo H is a tumor associated antigen (TAA) commonly found on a variety of tumor cells including breast cancer cells. KLH improves antigenic immune recognition and T-cell responses.

Clinical Trials

View Clinical Trials for adagloxad simolenin

Adagloxad simolenin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating adagloxad simolenin, 1 is phase 3 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for adagloxad simolenin clinical trials.

Invasive breast carcinoma is the most common disease being investigated in adagloxad simolenin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Adagloxad Simolenin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating adagloxad simolenin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
obi822, obi 822, opt-822, obi-822
NCIT ID [1]:
C99766

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.